The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Rahul Parikh
Stock and Other Ownership Interests - IBRX (I)
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Benjamin Herzberg
Honoraria - Boxer Capital; Eisai; IDEOlogy Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Amgen; Arvinas; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; IDEAYA Biosciences; Johnson and Johnson; Lilly
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; IDEAYA Biosciences (Inst); Lilly (Inst); Monte Rosa Therapeutics (Inst); Nested Therapeutics (Inst); Prelude Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Mark Stein
Stock and Other Ownership Interests - Rafael Holdings
Consulting or Advisory Role - Exelixis; GI Innovation; Johnson & Johnson/Janssen
Research Funding - ARTBIO (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); DualityBio (Inst); Exelixis (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Regeneron (Inst); Telix Pharmaceuticals (Inst); Xencor (Inst)
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Gatorade Company (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Medpace (Inst); ModeX Therapeutics (Inst); OncoScope (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Pyxis (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Arcus Biosciences (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Beijing Avistone Biotechnology (Inst); Bicara Therapeutics (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Foundation Bio (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Kumquat Biosciences (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); Pierre Fabre (Inst); ProfoundBio (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Scorpion Therapeutics (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Benjamin Garmezy
Consulting or Advisory Role - Abbvie (Inst); Adaptimmune (Inst); Adicent Therapeutics (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Seagen (Inst); Specialty Networks (Inst); Takeda (Inst); Xencor (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adcentrx Therapeutics (Inst); Adicet Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); AVEO (Inst); Bicycle Therapeutics (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Halda Therapeutics (Inst); Harbour BioMed (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Merck (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)
 
Alexander Philipovskiy
Research Funding - Abbvie (Inst); Abbvie (Inst); Astellas Pharma (Inst); BeiGene (Inst); Frontier Med (Inst); GlaxoSmithKline (Inst); Immuneering (Inst); Janssen Research & Development (Inst); Loxo/Lilly (Inst); Monte Rosa Therapeutics (Inst)
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Biohaven Pharmaceuticals; EMD Serono; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - AADi (Inst); Flare Therapeutics (Inst); Janssen (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
Other Relationship - DAVA Oncology
 
Alissa Cooper
Honoraria - Ideology Health; Intellisphere; MedStar Health; MJH Life Sciences; Physician's Education Resource, LLC
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Regeneron
Research Funding - Abbvie (Inst); Amgen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Manav Korpal
Employment - Monte Rosa Therapeutics
Consulting or Advisory Role - Monte Rosa Therapeutics
 
Maciej Cabanski
Employment - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Monte Rosa Therapeutics
 
Carolina Perdomo Ortiz
No Relationships to Disclose
 
Ralph Tiedt
Employment - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Monte Rosa Therapeutics; Novartis
 
Lisa Cleary
Consulting or Advisory Role - Monte Rosa Therapeutics
 
Tess Schmalbach
Consulting or Advisory Role - Monte Rosa Therapeutics
 
Markus Warmuth
Employment - Monte Rosa Therapeutics
Leadership - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Monte Rosa Therapeutics
 
Filip Janku
Employment - Monte Rosa Therapeutics
Leadership - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Cardiff Oncology; Monte Rosa Therapeutics
Consulting or Advisory Role - Cardiff Oncology
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)